THE DISEASE ITSELF
In order to understand the new oral agents for diabetes one must understand the ailment itself. Diabetes mellitus is a metabolic disorder which results from an actual or relative deficiency of insulin. The exact causation of diabetes mellitus is not as yet entirely clear. Predisposition to the disease is largely hereditary. Because of deficiency of insulin, the body is unable to properly utilize food-principally carbohydrate, but also protein and fat. The treatment for diabetes mellitus, therefore, is a diet reduced in carbohydrate and calories and, when necessary, exogenous insulin.
It is difficult to recall any medication which has saved more lives, or permitted resumption of a normal mode of living for as many individuals, as has insulin. Authorities agree that insulin plays a vital part in delaying the onset of the degenerative vascular lesions which are now the number one problem in diabetes. It is necessary to bear in mind By
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HISTORY OF THE ORAL HYPOGLYCEMIC AGENTS
Medical science has conducted a long search for a safe, effective, oral medication to be used in the treatment of diabetes mellitus. Until the present era, no compound which could meet the tests of both safety and efficacy was found.
It was a chance medical discovery during a typhoid fever epidemic in France in 1942 that led to the hope that sulfa-related compounds might be helpful in the treatment of diabetes. During that epidemic Janbon, a French clinician, treated his typhoid patients with a new sulfonamide compound developed in Germany. However, several of these emaciated patients developed convulsions after taking the new drug and some died. It was later determined that the convulsions resulted from abnormally low blood sugar levels. After experimen-tation, Loubatieres, a French physiologist, concluded that the sulfonamide derivative lowered the blood sugar by stimulating the islet cells of the pancreas to release more insulin. However, no attempt was made to use sulfa-related compounds with human subjects at that time because laboratory animals treated with them developed liver and renal damage.
But in 1953 interest in oral hypoglycemic agents was reawakened. In 1955 German scientists announced that two new, less toxic arylsulfonylurea compounds -carbutamide (BZ55) and tolbutamide -had proved valuable in the treatment of some cases of maturity-onset diabetes. Carbutamide and tolbutamide were subjected to intensive study and clinical trial by selected medical groups in the United States and Canada. Carbutamide was withdrawn from further study in the United States in 1956 because it was thought to have too high a toxicity rate (it is still being used in Europe). The study of tolbutamide was continued, however, resulting in its release by the United States Food and Drug Administration in 1957. The search for other compounds which might be effective in the oral treatment of diabetes was continued. The second oral hypoglycemic agent to be released in the United States was chlorpropamide which was made available in November 1958. Phenformin, marketed in March 1959, was the third to be released. No doubt there will be other oral agents for diabetes as time goes on.
The three oral compounds now being used in the treatment of some diabetic patients are not aAy form of insulin. One frequently hears them referred to as oral insulin, but this is an error. They are classified as hypoglycemic (blood sugar lowering) agents. Two are arylsulfonylurea compounds and one is a biguanide compound. They cannot be called true insulin substitutes because they are incapable of producing certain desirable metabolic effects of which only insulin itself is capable.
TOLBUTAMIDE (ORINASE)
Tolbutamide, sold by prescription under the trade name of Orinase*, is an arylsulfonylurea compound which has the ability to lower the blood sugar in some diabetic subjects. Research has established that tolbutamide is effective only when the pancreatic islet cells are apparently still capable of producing fair amounts of insulin. The compound is thought to lower the blood sugar by stimulating the islet cells of the pancreas to secrete or release more insulin, and by inhibiting the release of· glucose by the liver. Patients who may respond to tolbutamide therapy are usually over 40 years of age with onset of diabetes in adult life. As a rule, they are mild diabetics whose disease is stable and uncomplicated. Although they cannot be controlled by diet alone, their insulin requirements in most cases are said to be less than 30 units a day. It has been reported that an occasional patient who was controlled effectively with tolbutamide for a few months later developed failure to respond to treatment. This is referred to as secondary failure.
Tolbutamide is contraindicated in the treatment of the following patients: the child, the long-term diabetic, the "brittle" and more severe adult diabetic, and the patient with complications. Known liver, renal, or thyroid pathology are contraindications to the use of any arylsulfonylurea compound.
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The daily maintenance dose ranges from 0.5 Gram to 2 Grams. A trial period is necessary to determine whether the patient is responsive to the drug and, if so, the correct dosage. Resumption of insulin therapy is necessary during times of stress such as acute illness, infection, gangrene, diabetic coma, and recovery from major surgery or severe injury.
CHLORPROPAMIDE (DIABINESE)
Chlorpropamide, obtainable by prescription under the trade name of Diabinese", is also an arylsulfonylurea compound. Chlorpropamide has been demonstrated to have the ability to lower the blood sugar in responsive subjects. Patients responsive to chlorpropamide are also those whose own pancreases are apparently still capable of producing fair amounts of insulin. One mode of action of the compound is thought to be the stimulation of the pancreatic islet cells to produce or release more insulin. A second mode of action is thought to be the inhibition of the release of glucose by the liver.
Candidates for treatment with chlorpropamide are some of the middle-aged and elderly diabetics with whom onset of the disease occured in adult life, and whose insulin requirements are low or moderate. Stability of the diabetes and freedom from complications are necessary. Chlorpropamide is contraindicated in the treatment of juvenile-type diabetes and in the treatment of the more severe adult-onset diabetes.
The daily maintenance dosage of chlorpropamide varies from 0.1 Gram to 1 Gram. A trial period is necessary to determine the responsiveness of the individual patient to the drug. Resumption of insulin therapy is necessary during acute illness, infection, coma, and gangrene, as well as during recovery from major surgery and severe injury.
PHENFORMIN (DBI)
Phenformin was released for prescription sale in the United States in March 1959 and is better known by its trade name of DBI**. DBI differs from tolbutamide and chlorpro-* product of Pfizer Laboratories ** product of U. S. Vitamin and Pharmaceutical Corporation pamide in that it is not a sulfonamide derivative. This drug is a biguanide compound (phenethylbiguanide). The name DBI-4iahetes number onewas derived from a code designation for the chemical compound. DBI is said to have blood sugar lowering effects even when the pancreatic islet cells are producing very little, if any, insulin. In this respect it again differs from the sulfonylureas. The mode of action of DBI is not entirely clear as yet, but it is thought to augment the hypoglycemic effect of insulin.
It does not increase the production of insulin by the islet cells. Because DBI can be used in juvenile-type diabetes, it can be said to be applicable to a wider range of patients than are the sulfonylureas.
It has been demonstrated that DBI can be used alone to achieve results similar to those obtained with the sulfonylurea compounds in the treatment of the less severe diabetics with onset in adult life. However, at the present time DBI is most frequently given in conjunction with insulin in the treatment of the more severe, labile diabetics. It is said to be of greatest value in attempts to stabilize the course of "brittle" or problem diabetics-juvenile as well as adultwho have been difficult to control smoothly with insulin alone. "Brittle" diabetics are those who fluctuate between high and low blood sugar values and are, therefore, prone to both insulin reactions and diabetic acidosis. Clinical trials have demonstrated that it has been possible to achieve a smoother course of management for some problem cases, and reduce the insulin dosage in varying amounts, by giving supplemental DB!. Authorities agree that DBI, like the other oral hypoglycemic agents, should not be used with children or the more severe adult-onset patients who are effectively and smoothly controlled with insulin and diet. THE NURSE NEEDS TO KNOW It will be some time yet-perhaps a few years-before the efficacy and safety of the oral hypoglycemic compounds over long-term usage have been definitely established. But all things must have a beginning.
Nurses need to know that simply because a diabetic patient falls into a certain age group, or type of patient, does not necessarily indicate that he will respond to treatment with the oral agent usually applicable to that group. Trial-transition periods are necessary to determine responsiveness.
Nurses need to emphasize to diabetic patients that no oral agent will be effective if a diet restricted in carbohydrate and calories is not meticulously and consistently followed. The patients need to have stressed that there can be no relaxation of good diabetes care. Good personal hygiene, proper exercise and rest, meticulous care of the feet, and daily examination of the urine are as important as ever.
The patient who is being treated with an oral agent needs to be impressed with the fact that he must report to his physician promptly if there is a reappearance of diabetic symptoms such as positive urine tests, thirst, and loss of weight. He must notify his physician at once if any symptoms which might be attributed to side effects of the compounds appear. Periodic check-ups are a necessity for blood determinations and possible dosage adjustment. careful determination to minimize the anorexia, nausea, and vomiting which is possible with improper use of this compound. A dosage adjustment period is recommended. During this period the dosage of DBI is adjusted specifically to the requirements of the individual diabetic patient. If the diabetic develops persistent gastro-intestinal side effects, or if there is a worsening of the diabetic condition, return to full insulin therapy is necessary. With DB! there is also a need for resumption of insulin therapy during coma, acute illness, gangrene, and recovery from major surgery and severe injury.
